Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07645950
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Montpellier - Val d'AurelleNot Yet Recruiting
NCT07645950Not Yet Recruiting
—
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Mon...
NCT07645469
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaFred Hutchinson Cancer CenterNot Yet RecruitingPhase 1
NCT07645469Not Yet Recruiting
Phase 1
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Di...Fred Hutchinson Cancer Ce...
NCT07643935
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of ResponseCentral Hospital, Nancy, FranceNot Yet Recruiting
NCT07643935Not Yet Recruiting
—
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timin...Central Hospital, Nancy,...
NCT07645170
Strain Counter-Strain vs Maitland Mobilization for Sacroiliac Joint PainUniversity of FaisalabadActive Not RecruitingNot Applicable
NCT07645170Active Not Recruiting
Not Applicable
Strain Counter-Strain vs Maitland Mobilization for Sacroiliac Joint PainUniversity of Faisalabad
NCT07644754
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory MetastasesLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07644754Not Yet Recruiting
Not Applicable
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level...Ludwig-Maximilians - Univ...
NCT07645560
A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic StrokeBeijing Tiantan HospitalNot Yet RecruitingPhase 2
NCT07645560Not Yet Recruiting
Phase 2
A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After...Beijing Tiantan Hospital
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07645521
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation Following Functional Endoscopic Sinus SurgeryMansoura UniversityCompletedNot Applicable
NCT07645521Completed
Not Applicable
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation...Mansoura University
NCT07643805
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCLThe First Affiliated Hospital with Nanjing Medical UniversityNot Yet RecruitingPhase 1
NCT07643805Not Yet Recruiting
Phase 1
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Pat...The First Affiliated Hosp...
NCT07644767
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty LtdNot Yet RecruitingPhase 2
NCT07644767Not Yet Recruiting
Phase 2
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty Lt...
NCT07644923
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated CoagulationNYU Langone HealthNot Yet RecruitingPhase 4
NCT07644923Not Yet Recruiting
Phase 4
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled Wit...NYU Langone Health
NCT07644624
Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Surgery (SLIDY)Hospital Universitari de BellvitgeNot Yet RecruitingNot Applicable
NCT07644624Not Yet Recruiting
Not Applicable
Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Sur...Hospital Universitari de...
NCT07646314
Comparative Effects of Post-Isometric Relaxation and Reciprocal Inhibition Techniques inPiriformis SyndromeRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646314Not Yet Recruiting
Not Applicable
Comparative Effects of Post-Isometric Relaxation and Reciprocal Inhibition Techn...Riphah International Univ...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07644416
Using Virtual Reality Travel to Reduce Loneliness in Older AdultsIndiana UniversityNot Yet RecruitingNot Applicable
NCT07644416Not Yet Recruiting
Not Applicable
Using Virtual Reality Travel to Reduce Loneliness in Older AdultsIndiana University
NCT07645053
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal SurgeryHospital Edmundo VasconcelosCompletedPhase 1
NCT07645053Completed
Phase 1
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal...Hospital Edmundo Vasconce...
Result Breakdown
Not yet recruiting16 (80%)
Completed2 (10%)
Active, not recruiting1 (5%)
Recruiting1 (5%)
not_applicable7 (35%)
Not Specified4 (20%)
Phase 14 (20%)
Phase 23 (15%)
Phase 42 (10%)